Showing 191-200 of 354 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Immunogenicity of workload-regulated beta cell states in type 1 diabetes | Regents of the University of Colorado | Matthew Wortham | Cures | 01-August-2026 to 31-July-2031 | $1,000,000.00 |
| Autoimmunity Screening for Kids (ASK) | Regents of the University of Colorado | Marian Rewers | Cures | 01-November-2024 to 31-October-2027 | $3,074,807.75 |
| Antigenic Targets of CD4 T cells across the stages of type 1 diabetes | Regents of the University of Colorado | Maki Nakayama | Cures | 01-August-2022 to 31-July-2026 | $749,998.87 |
| Validation of Enzyme-linked immunosorbent assay (ELISA) to detect insulin autoantibodies | Regents of the University of Colorado | Liping Yu | Cures | 01-June-2025 to 31-May-2027 | $453,852.00 |
| Innovating Methods for AssessinG INsulin Action in Type ONe diabetes (IMAGINATiON) | Regents of the University of Colorado | Kristen Nadeau | Improving Lives | 01-December-2021 to 31-December-2026 | $445,816.29 |
| Islet autoantibody concordance and metabolic monitoring of individuals identified at risk for type 1 diabetes through population-based screening | Regents of the University of Colorado | Kimber Simmons | Cures | 01-July-2023 to 31-December-2026 | $750,000.00 |
| Investigating the association between environmental contaminants and progression to autoimmune disease | Regents of the University of Colorado | Jill Norris | Cures | 01-September-2026 to 31-August-2027 | $149,999.97 |
| Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes | Regents of the University of Colorado | Jessica Kendrick | Improving Lives | 01-October-2022 to 31-October-2027 | $899,235.00 |
| EFFICACY AND SAFETY OF ONCE WEEKLY SEMAGLUTIDE IN ADULTS WITH OBESITY AND INADEQUATELY CONTROLLED TYPE 1 DIABETES USING HYBRID CLOSED-LOOP SYSTEM | Regents of the University of Colorado | Janet Snell-Bergeon | Improving Lives | 01-November-2022 to 31-October-2027 | $2,282,771.83 |
| Engaging Interest Holders to Measure Psychological Impacts and Patient-Reported Outcomes of Treatment with Disease-Modifying Therapy in T1D | Regents of the University of Colorado | Holly O’Donnell | Cures | 01-August-2026 to 31-July-2029 | $846,023.00 |